These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3129240)

  • 41. [Complete androgen blockage in the treatment of metastatic prostate cancer].
    Matzkin H; Braf Z
    Harefuah; 1994 Mar; 126(5):260-3. PubMed ID: 8188104
    [No Abstract]   [Full Text] [Related]  

  • 42. Combination of Anandron with orchiectomy in treatment of metastatic prostate cancer. Results of a double-blind study.
    Beland G
    Urology; 1991; 37(2 Suppl):25-9. PubMed ID: 1992600
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Fatal fulminating hepatitis caused by nilutamide. A new case].
    Marty F; Godart D; Doermann F; Mérillon H
    Gastroenterol Clin Biol; 1996; 20(8-9):710-1. PubMed ID: 8977826
    [No Abstract]   [Full Text] [Related]  

  • 44. Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.
    Harris MG; Coleman SG; Faulds D; Chrisp P
    Drugs Aging; 1993; 3(1):9-25. PubMed ID: 8453188
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group.
    Lancet; 2000 Apr; 355(9214):1491-8. PubMed ID: 10801170
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antiandrogen withdrawal syndrome with nilutamide.
    Gomella LG; Ismail M; Nathan FE
    J Urol; 1997 Apr; 157(4):1366. PubMed ID: 9120950
    [No Abstract]   [Full Text] [Related]  

  • 47. [Tolerance and clinical and biological responses during the first 6 months of treatment with 1-month sustained release LHRH agonists leuprolerin and triptolerin in patients with metastatic prostate cancer].
    Abbou CC; Lucas C; Leblanc V
    Prog Urol; 1997 Dec; 7(6):984-95. PubMed ID: 9490144
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Provocation test coupled with bronchoalveolar lavage in diagnosis of drug (nilutamide)-induced hypersensitivity pneumonitis.
    Akoun GM; Liote HA; Liote F; Gauthier-Rahman S; Kuntz D
    Chest; 1990 Feb; 97(2):495-8. PubMed ID: 2298082
    [TBL] [Abstract][Full Text] [Related]  

  • 49. LHRH analogues in combination with an anti-androgen in the treatment of advanced disease.
    Denis L
    Horm Res; 1989; 32 Suppl 1():66-7; discussion 68. PubMed ID: 2533158
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacology of nilutamide.
    Gaillard-Moguilewsky M; de Gery A; Ulmann A
    Cancer; 1993 Dec; 72(12 Suppl):3828-9. PubMed ID: 8252498
    [No Abstract]   [Full Text] [Related]  

  • 51. [The antiandrogen treatment of patients with prostatic cancer and bone metastases].
    Matveev BP; Bukharkin BV; Zhumagazin ZhD
    Urol Nefrol (Mosk); 1993; (1):10-4. PubMed ID: 7941115
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Stimulation of erythropoiesis by the non-steroidal anti-androgen nilutamide in men with prostate cancer: evidence for an agonistic effect?
    Decensi A; Torrisi R; Fontana V
    Br J Cancer; 1994 Mar; 69(3):617-9. PubMed ID: 8123500
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Newer methods of hormonal therapy for prostate cancer.
    Soloway MS
    Urology; 1984 Nov; 24(5 Suppl):30-8. PubMed ID: 6437034
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Total androgen ablation: Canadian experience.
    Béland G; Elhilali M; Fradet Y; Laroche B; Ramsey EW; Trachtenberg J; Venner PM; Tewari HD
    Urol Clin North Am; 1991 Feb; 18(1):75-82. PubMed ID: 1992574
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comment: clinical experiences of visual disturbances with nilutamide.
    Dijkman GA; Klotz LH; Diokno AC; Zippe CD
    Ann Pharmacother; 1997 Dec; 31(12):1550-2. PubMed ID: 9416403
    [No Abstract]   [Full Text] [Related]  

  • 56. New hormonal therapy in prostate cancer: combined use of a pure antiandrogen and an LHRH agonist.
    Labrie F; Dupont A; Belanger A; Lefebvre FA; Cusan L; Raynaud JP; Husson JM; Fazekas AT
    Horm Res; 1983; 18(1-3):18-27. PubMed ID: 6411578
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer.
    Nakabayashi M; Regan MM; Lifsey D; Kantoff PW; Taplin ME; Sartor O; Oh WK
    BJU Int; 2005 Oct; 96(6):783-6. PubMed ID: 16153200
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Watchful waiting beats androgen deprivation therapy in early prostate cancer.
    Brower V
    J Natl Cancer Inst; 2008 Nov; 100(21):1494-6. PubMed ID: 18957680
    [No Abstract]   [Full Text] [Related]  

  • 59. [Therapy of metastatic prostatic cancer by orchiectomy plus Anandron versus orchiectomy plus placebo. Initial results of a randomized multicenter study].
    Knönagel H; Bolle JF; Hering F; Senn E; Hodel T; Neuenschwander H; Biedermann C
    Helv Chir Acta; 1989 Aug; 56(3):343-5. PubMed ID: 2681086
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ocular toxicity of Anandron in patients treated for prostatic cancer.
    Harnois C; Malenfant M; Dupont A; Labrie F
    Br J Ophthalmol; 1986 Jun; 70(6):471-3. PubMed ID: 3718913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.